Aug 28, 2026 · 27 min
Moderna bets cancer vaccine can outlast its COVID boom
The Cancer Vaccine That Could Save Moderna
The vaccine’s melanoma results offer patients a potential new treatment while testing whether Moderna can turn mRNA expertise into a durable business.
- 1Moderna’s personalized mRNA vaccine showed encouraging phase two results against recurrence and spread in high-risk melanoma.
- 2Merck’s Keytruda partnership helped move the individualized treatment from a risky internal bet toward phase three testing.
- 3FDA review, unreleased trial details, cost, and expansion beyond melanoma still stand between the vaccine and patients.
Don't miss
Moderna employees emotionally celebrated phase two results that appeared to reduce recurrence and spread of high-risk melanoma.
The brief
Moderna built its fortune on COVID-19, then faced a sharp downturn; an experimental personalized melanoma vaccine has revived hopes for patients and the company.
The company’s mRNA platform can instruct the immune system, but cancer demanded a costly, individualized approach that many inside Moderna initially viewed as too uncertain.
A partnership with Merck paired Moderna’s vaccine with Keytruda, combining personalized treatment with an established immunotherapy and the clinical expertise needed to test it.
Phase two results appeared strong enough to justify a large phase three trial, prompting an emotional celebration inside Moderna while detailed findings remained unreleased.
The vaccine still needs FDA approval, and questions about regulatory scrutiny, cost, and whether the approach can work beyond melanoma remain unanswered.
Stéphane Bancel
Lane Florsheim
Keytruda
Food and Drug AdministrationListen to the full episode and explore every guest, topic, and moment on PodLume.